Phathom Pharmaceuticals, Inc. — Form 8-K Summary
Filing date: November 8, 2021. The company reported under Items 2.02 and 9.01 that it issued a press release announcing financial results for the quarter ended September 30, 2021.
Business Context and Reporting Period
Phathom Pharmaceuticals is a Delaware-incorporated, emerging growth pharmaceutical company whose common stock trades on Nasdaq under the symbol PHAT. The filing concerns quarterly results for the period ended September 30, 2021.
Financial Results and Liquidity
The filing text provided does not include the financial results or the related press release. Accordingly, it does not provide clear values for revenue, net income or loss, cash flow, operating expenses, margins, debt, cash, liquidity, or other financial metrics.
Changes Versus Prior Period
The filing text does not provide sufficient information to assess changes versus the comparable prior period.
Guidance, Outlook, Risks, and Unusual Items
No guidance, outlook, management commentary, risk updates, contingencies, or unusual items are included in the provided filing text. Exhibit 99.1 is identified as the company’s November 8, 2021 press release but its contents are not provided.
Important Facts to Verify
- Verify the quarterly revenue, operating expenses, net loss, and loss per share in Exhibit 99.1.
- Verify cash, cash equivalents, investments, debt, and expected liquidity runway as of September 30, 2021.
- Review year-over-year and sequential changes in research and development and general and administrative expenses.
- Check for any updated clinical, regulatory, commercialization, financing, or corporate-development information in the omitted press release.
- Note that the Form 8-K states the information, including Exhibit 99.1, is furnished rather than filed for purposes of Section 18 liability, except as otherwise expressly incorporated.